| Market Cap | 7.77M | P/E | - | EPS this Y | 64.70% | Ern Qtrly Grth | - |
| Income | -22.76M | Forward P/E | -0.18 | EPS next Y | 56.20% | 50D Avg Chg | -4.00% |
| Sales | 420k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -21.00% |
| Dividend | N/A | Price/Book | 0.77 | EPS next 5Y | - | 52W High Chg | -74.00% |
| Recommedations | 2.00 | Quick Ratio | 0.77 | Shares Outstanding | 1.46M | 52W Low Chg | 24.00% |
| Insider Own | 6.41% | ROA | -86.33% | Shares Float | 1.16M | Beta | 0.55 |
| Inst Own | 14.39% | ROE | -272.63% | Shares Shorted/Prior | 351.07K/24.34K | Price | 0.62 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 71,251 | Target Price | 11.00 |
| Oper. Margin | -17,290.32% | Earnings Date | May 14 | Volume | 24,738 | Change | 0.98% |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.
| Roth MKM | Buy | May 3, 24 |
| Brookline Capital | Hold | Dec 19, 23 |
| Roth MKM | Buy | Dec 19, 23 |